Small-Molecule Inhibitors Targeting eIF4A in Leukemia
-
Published:2021-12-07
Issue:7
Volume:22
Page:559-566
-
ISSN:1389-2037
-
Container-title:Current Protein & Peptide Science
-
language:en
-
Short-container-title:CPPS
Affiliation:
1. College of Life Sciences, China Jiliang University, Hangzhou 310018, China
2. Department of Hematology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China
Abstract
Eukaryotic translation initiation factor 4A (eIF4A) is a highly conserved DEAD-box RNA
helicase in eukaryotes with ATPase and RNA helicase activities. eIF4A plays an important role in capdependent
translation at the initiation of mRNA translation, and carcinoma signal transduction pathways
are focused on cap-dependent translation. eIF4A is highly expressed in a variety of cancers, and
its high expression is associated with the degree of leukemia progression. Therefore, eIF4A, as a target
for tumor therapy, has become a hot research topic. Many small-molecule inhibitors targeting eIF4A
have been demonstrated in preclinical cancer model trials. The purpose of this review is to describe the
function of eIF4A and the development of eIF4A targeting inhibitors.
Funder
Natural Science Foundation of Zhejiang Province, China
Science and Technology Project of Hangzhou
National Natural Science Foundation of China
Publisher
Bentham Science Publishers Ltd.
Subject
Cell Biology,Molecular Biology,Biochemistry,General Medicine